Santen Pharmaceutical Co., Ltd. (TYO:4536)
Japan · Delayed Price · Currency is JPY | Market Cap | 699.35B +21.3% |
| Revenue (ttm) | 291.62B -2.8% |
| Net Income | 37.36B +3.1% |
| EPS | 113.80 +9.8% |
| Shares Out | 321.69M |
| PE Ratio | 19.10 |
| Forward PE | 18.19 |
| Dividend | 42.00 (1.93%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 1,160,600 |
| Open | 2,197.00 |
| Previous Close | 2,174.00 |
| Day's Range | 2,160.50 - 2,205.00 |
| 52-Week Range | 1,458.00 - 2,254.00 |
| Beta | 0.25 |
| Analysts | Buy |
| Price Target | 2,303.33 (+6.07%) |
| Earnings Date | Aug 6, 2026 |
About Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglan... [Read more]
Financial Performance
In fiscal year 2026, Santen Pharmaceutical's revenue was 291.62 billion, a decrease of -2.79% compared to the previous year's 300.00 billion. Earnings were 37.36 billion, an increase of 3.07%.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for 4536 stock is "Buy." The 12-month stock price target is ¥2,303, which is an increase of 6.07% from the latest price.
News
Clearside Biomedical’s partner signed new collaboration agreement with Santen
Clearside Biomedical (CLSD) announced today that the Company’s Asia-Pacific partner, Arctic Vision, has signed a new commercial collaboration agreement with Santen Pharmaceutical (SNPHY) for ARVN001, ...
Ocular Therapeutix appoints Graves to board of directors
Ocular Therapeutix (OCUL) announced the appointment of Adrienne Graves, Ph.D., to its Board of Directors. As the former CEO of Santen (SNPHY), the US subsidiary of a 130-year-old Japanese pharmaceutic...
Santen Pharmaceutical upgraded to Buy from Neutral at Citi
Citi analyst Hidemaru Yamaguchi upgraded Santen Pharmaceutical to Buy from Neutral with a price target of 1,400 yen, up from 1,100 yen. The analyst says the company’s restructuring-led profit recovery...